Retatrutide Skin Sensitivity: How Common It Is, How Long It Lasts, and When to Worry

By The RX Index Editorial Team · Last verified October 15, 2026

Yes, retatrutide skin sensitivity is a reported side effect. Doctors call it dysesthesia: burning, tingling, or skin that hurts to the touch. In five Phase 3 trials, it affected 4.4%–20.9% of people assigned to 12 mg, versus 0%–1.3% on placebo. Most cases were mild to moderate; some were severe. The reviewed studies give no fixed recovery time. Trial sources.

Retatrutide is not FDA-approved (FDA). Dose and the people studied affect the reported rates. A product from outside a trial adds a different problem: the trial numbers cannot verify what was in it. Retatrutide skin sensitivity is real, but it isn't unique. Wegovy's current label reports it in 22% of people on the 7.2 mg dose (FDA label).

The question almost nobody answers well is how long it lasts. We pulled the recovery findings from the sources we reviewed into one table below. But first, the signs that mean you shouldn't wait.

When to get help right away

Burning, tingling, or sore-to-touch skin can happen without a visible rash. But normal-looking skin does not rule out a problem that needs care. This table can't tell you what's causing your symptoms. Use the warning signs below to decide when to seek help—not to diagnose yourself.

Don't let a study-team callback, a quiz, or this page slow you down if you have an emergency sign.

Jump to: Trial rates · Recovery · What helps · Clinician note.

What does retatrutide skin sensitivity feel like?

It can feel like burning, tingling, prickling, or sunburn-like soreness when nothing has hurt the skin. Light touch from clothes, sheets, or shower water can feel painful. In the Phase 2 retatrutide trial, the reported skin-sensation events had no visible skin changes. (NEJM, 2023; IASP terminology)

Picture the day after a bad sunburn, but with no sun and no redness.

Three medical words get used for this, and they overlap. They describe how a sensation feels, not what caused it (IASP terminology).

The descriptions in the last column are examples, not quotes from real patients.

Each study counted these feelings a little differently:

• Retatrutide Phase 3 (TRIUMPH) trials: "skin burning sensation and related adverse events," in Lilly's own definition (Lilly Medical).
• TRANSCEND-T2D-1 (diabetes trial): "sensitive skin" was the most common event reported (The Lancet, 2026).
• Retatrutide Phase 2 trial: called it "cutaneous hyperesthesia and skin sensitivity" (NEJM, 2023).
• Wegovy's label: groups 11 terms together, including allodynia, burning sensation, pain of skin, sensitive skin, and paresthesia (FDA label).

That's why three articles can use different words for related skin sensations. The terms overlap; they do not all mean the same thing.

A few neighbors that aren't this side effect: loose skin after weight loss, hair loss (see GLP-1 hair loss), and a red patch only at the injection spot.

How common is retatrutide skin sensitivity?

At the 12 mg dose, between 4.4% and 20.9% of people reported it across five Phase 3 trials, compared with 0% to 1.3% on placebo. The highest number came from the smallest of the five, 445 people with knee arthritis. In the largest, 2,339 adults without diabetes, it was 12.5%.

Here are the rates from the five Phase 3 trials we reviewed, with who was studied and where each number comes from. The dose columns show assigned target-dose groups—not doses to choose for yourself.

"Not studied" means no group was assigned that target dose. Lower doses could still be used while participants worked up to their assigned target. It doesn't mean zero events. The TRANSCEND percentages are our math from the paper's own counts (6 of 134, 3 of 133, 6 of 136, and 0 of 134). The paper prints them rounded to whole numbers.

What a number like 12.5% means. In TRIUMPH-1, 73 of the 582 people in the 12 mg safety group reported it during the 80-week treatment period. The safety group includes people who received at least one study dose. That's about 1 in 8 people in that group. It isn't 1 in 8 injections, and it isn't a forecast for someone using a product from outside a trial.

Why the range is so wide.

• The trials studied different people (with or without diabetes, heart disease, or knee arthritis) for different lengths of time.
• More dose usually meant more cases, but not always. In TRANSCEND, 9 mg had the fewest. In TRIUMPH-3, 9 mg and 12 mg were the same.
• The Lilly releases we reviewed don't explain why TRIUMPH-4's rate was so much higher.

Why you keep seeing "1 in 5." That's TRIUMPH-4, the highest of the five. Lined up at 12 mg, the five rates run from about 1 in 23 to 1 in 5, and the middle one is 7.3%. These trials weren't built to be averaged together, so we don't give one blended number.

What we actually verified (October 15, 2026)

• Read the TRIUMPH-1 (NEJM) and TRANSCEND-T2D-1 (Lancet) adverse-event tables ourselves. Both papers were reached through reproduced copies, not the publishers' sites. We checked each skin-sensation count against its denominator.
• TRIUMPH-2, -3, and -4 rates come from Lilly's own releases. We also checked Lilly's medical-information page. We haven't read the full TRIUMPH-2 paper.
• Read the Phase 2 paper and its appendix, including the recovery footnote and the placebo column.
• Read the current Wegovy label (revised June 2026), Zepbound label (revised August 2026), and New Zealand's March 2026 safety notice.
• Checked the FDA's statement on retatrutide and compounding, Lilly's physician-requested expanded-access information, and the official help sources linked above.
• What we couldn't confirm: a dependable number of days until retatrutide skin sensitivity clears. The sources we reviewed don't provide one. We didn't test any product, examine anyone, or check what's in any vial.

Does retatrutide skin sensitivity go away?

Most dysesthesia events in TRANSCEND-T2D-1 resolved while people kept taking retatrutide. But three were severe and two people stopped treatment. The Phase 2 appendix also records unresolved events at follow-up, without separating their outcomes by treatment group. The sources we reviewed do not give a reliable number of days to recovery.

Put plainly: most cases faded during the retatrutide diabetes trial, but that does not promise recovery for every person. And in the Wegovy trials—not retatrutide—symptoms returned in 17 of 38 people whose symptoms had resolved before they went back up to 7.2 mg: almost half. The label describes what happened; it was not a randomized test of which symptom treatment works best.

We won't give you a recovery deadline. The retatrutide sources we reviewed don't support a promise that it clears in two weeks, four weeks, or any other fixed time. If it affects sleep, clothing, or daily life, tell your clinician rather than waiting for that deadline.

Does zinc, an antihistamine, or anything else help?

None of the trial papers, labels, or safety notices we reviewed describe a proven home treatment for this. A tip on a forum isn't evidence that the feeling comes from a missing nutrient or an allergy. Trial protocols put dose changes under clinician supervision.

"We didn't find it" is a limit of our review. It isn't proof a remedy can never help.

Why does retatrutide cause skin sensitivity?

The studies we reviewed do not explain the cause. Retatrutide acts on three hormone targets (GIP, GLP-1, and glucagon). Semaglutide acts on GLP-1 alone and its label also lists dysesthesia, so the symptom is not specific to triple-target medicines. On Wegovy's label, the rate went up with higher doses and higher drug levels in the blood. (NEJM, 2023; FDA Wegovy label)

You'll find sites that say glucagon is the culprit. The studies we reviewed do not establish that explanation.

A few things the evidence does say:

• It isn't unique to retatrutide. Wegovy and Zepbound both list it (FDA Wegovy label; Zepbound label).
• New Zealand's regulator has flagged altered skin sensations with GLP-1 medicines. It told doctors to consider GLP-1 medicines as a possible cause when a patient comes in with altered skin sensations (Medsafe).
• It showed up before Phase 3. The 2023 Phase 2 retatrutide trial reported it in about 7% of people on retatrutide versus 1% on placebo (NEJM, 2023).

Is it nerve damage, or a sign the medicine is working?

The trials don't describe it as nerve damage. Cases were mostly mild to moderate, and in the Phase 2 trial none came with visible skin changes. There's also no evidence it means the medicine is working: in Phase 2, it did not appear tied to how much or how fast people lost weight. (NEJM, 2023)

The trials we reviewed do not settle long-term nerve outcomes. A name like "dysesthesia" describes a feeling, not its cause. So numbness that spreads, weakness, or a loss of feeling needs a real exam. Don't assume it's an expected side effect (see the table at the top).

What if your product came from an online seller?

Clinical-trial results don't tell you what's in a product sold under the retatrutide name. The FDA says retatrutide can't be used in compounding under federal law, and it has warned companies selling it as "for research purposes." Skin symptoms on a product like that could be this side effect, or they could come from the product itself.

The retatrutide trial rates above came from study medication given under supervised protocols, with doctors checking in. The FDA says unapproved drugs sold online may contain the wrong ingredient, too much, too little, or none at all (FDA).

That's why yellowing eyes or dark urine needs prompt care, even without itchy skin.

You don't need a perfect explanation before asking for help. Be honest about what you used, and bring the package or a photo. More on telling real from fake: how to avoid fake GLP-1 medications online.

What to tell your clinician or study team

A useful report says what changed, when it started, where it is, and what else you've taken. You don't need a diagnosis, and you shouldn't guess an amount you don't know. If you're in a trial, call your study team, since they know your study protocol.

Here's a hypothetical. Say your shirt suddenly hurts against one side of your back, and you can't confirm the strength printed on a vial. Write down where it is, when it started, and whether the skin looks different. Then put "unknown" for the amount instead of guessing.

Use the note below to get ready for the call. Don't let filling it out delay urgent care.

My skin-sensation note I developed a new skin sensation after using a product labeled [name]. I am [in a clinical trial / under a clinician's care for this / using a product from another source / not sure]. It began on [date/time]. It feels like [burning / tingling / painful to touch / numbness / other]. It's on my [body area], on [one side / both sides / not sure]. My skin looks [normal / red / rash or blisters / other]. Since it started, it's [better / worse / the same], and it affects my [sleep / clothing / work / other]. Other symptoms: [list, or "none noticed"]. The last amount I used was [exact amount and units as written, or "unknown"] on [date/time]. I have [the package / a photo / the lot number / none of these]. Other medicines, supplements, or peptides I use: [list]. Things I've already tried for this: [list]. What should I do now, and which symptoms mean I should get urgent care?

After you've gotten care, you can report a suspected side effect or a product problem to the FDA through MedWatch. Patients can report directly. A report doesn't replace medical care. If you're in a trial, tell your study team too.

Need help starting that conversation? See how to talk to your doctor about GLP-1s.

Do Zepbound and Wegovy cause skin sensitivity too?

Yes. Both list it, at very different rates. In their own trials, Zepbound reported it in 0.2% to 0.4% of people, Wegovy 2.4 mg in 2% to 6%, and Wegovy 7.2 mg in 22%. These are separate trials with different people and slightly different definitions, so they aren't a head-to-head ranking.

Two honest caveats. Switching medicines doesn't guarantee this won't happen: it appears in retatrutide trial reports and both approved-drug labels. And if you have symptoms right now, a clinician should look at them before anyone talks about switching.

More on the highest-dose Wegovy: Wegovy HD side effects. Side effects across the class: GLP-1 side effects comparison chart.

Can you get retatrutide legally right now?

Not as a routine pharmacy purchase or regular prescription. Retatrutide isn't FDA-approved, and the FDA says it can't be used in compounding under federal law. U.S. access is through an authorized clinical trial or physician-requested expanded access, subject to Lilly's eligibility review and the required FDA and ethics-board approvals.

The FDA's current statement adds that retatrutide isn't part of any approved drug and hasn't been found safe and effective for any condition (FDA). Lilly's retatrutide-specific expanded-access page says the treating physician must request access; patients cannot apply directly. Availability depends on eligibility, supply, and geography. Meeting the initial criteria does not guarantee access (Lilly Medical, reviewed August 26, 2026). Full details on trials and special access: retatrutide availability.

If cost or access led you to an online product, discuss approved options once your symptoms have been reviewed. The RX Index's Find My GLP-1 Path tool can help you explore a suggested path and provider pricing based on your goals, budget, insurance, and situation. It is not a symptom check or a check of your plan's coverage or copay.

For a side-by-side of approved options, see legal alternatives to retatrutide.

How we checked this

We built this page from the trial papers, Lilly's own data, the FDA's label and statements, and a national regulator's safety notice. Where papers gave counts, we checked them against their denominators. We labeled where each number came from. We didn't average different trials, diagnose anyone, or test any product.

The RX Index is the independent GLP-1 decision resource that scores telehealth providers and treatment paths on clinical legitimacy, care quality, transparency, access, and cost, so readers can choose the path that fits their situation.

Our source order:

1. Regulators (FDA, Medsafe).
2. Peer-reviewed trial papers.
3. Lilly's releases and medical-information pages, labeled as company data.
4. Approved-drug labels, used for comparisons and warning-sign context—not as a retatrutide label.
5. Health-agency guidance (MedlinePlus, NIH) for warning signs.

Questions about zinc and other remedies guided what we checked. We never treated online anecdotes as medical evidence.

For the full side-effect picture (stomach effects, heart rate, blood sugar), see retatrutide side effects. For how retatrutide compares overall, see retatrutide vs. tirzepatide.

Retatrutide skin sensitivity FAQ

How long does retatrutide skin sensitivity last?

The retatrutide sources we reviewed do not give a reliable number of days to recovery. In TRANSCEND-T2D-1, most events resolved during treatment, but 3 were severe and 2 people stopped treatment. Expect a clinician, not a calendar, to guide you (The Lancet).

Does zinc help retatrutide skin sensitivity?

We found no controlled study showing zinc treats it in the sources we reviewed. High-dose zinc taken for weeks can lower your copper levels, so a supplement isn't automatically harmless. Ask a clinician before adding one (NIH).

Why did it seem worse after a dose change?

In several trials, higher assigned doses had more cases, but the pattern wasn't consistent. In one trial the middle dose had the fewest. Tell your clinician the timing. It doesn't tell you what dose change to make on your own.

Does retatrutide cause skin sensitivity?

Yes. It was reported more often than on placebo in all five Phase 3 trials reviewed here, in 4.4% to 20.9% of people assigned to the 12 mg group. Most cases were mild to moderate, but severe cases occurred. The trial table shows the populations and sources.

Is retatrutide dysesthesia permanent?

The evidence can't promise it always clears, and it doesn't show an unresolved case is permanent. The Phase 2 appendix lists 16 events resolved, 2 resolving during treatment, and 2 unresolved at the 4-week follow-up; it includes placebo and does not assign those outcomes to treatment groups. On Wegovy 7.2 mg—a different drug—18% did not report recovery during the trial (Phase 2 appendix; FDA Wegovy label).

Can skin sensitivity happen without a rash?

Yes. The Phase 2 trial reported altered skin sensations without visible skin changes. Still tell your clinician whether your skin looks normal, red, or blistered. Looks alone can't rule out something else (NEJM, 2023).

Should I take my next dose?

This page can't safely make that call from a description. Ask your study team or the clinician responsible for your care first. Use 911 for emergency signs, and Poison Control (1-800-222-1222) for a reaction to a product you're unsure about.

Is skin sensitivity a sign retatrutide is working?

The evidence reviewed does not support using this symptom as a sign of successful treatment. In the Phase 2 trial, the events did not appear linked to how much or how fast people lost weight (NEJM, 2023).

Will switching to Zepbound or Wegovy stop it?

There's no guarantee. Both labels list dysesthesia. Zepbound's reported rate was 0.2% to 0.4% in its own trials, but that does not establish that switching will stop your symptoms. Get current symptoms checked before considering a switch (Zepbound label; Wegovy label).

How do I report it?

Use the FDA's MedWatch program. Patients can report directly. If you're in a trial, tell your study team too. For urgent symptoms, get medical help before filing a report.

Sources

Source text checked October 15, 2026. Publication and label-revision dates below are separate from our check date. The TRIUMPH-2 full paper was not read; its row uses Lilly's detailed release.

• Jastreboff AM, et al. TRIUMPH-1. N Engl J Med. Published September 29, 2026. Journal DOI; reproduced paper used for this page, Table 3 and safety text.
• Bajaj HS, et al. TRANSCEND-T2D-1. Lancet. Published June 6, 2026. Journal DOI; reproduced paper read for this page, Table 2 and the dysesthesia paragraph.
• Bellido V, et al. TRIUMPH-2. Lancet. Published September 29, 2026. Journal DOI. Publication confirmed through Lilly's release and medical-information references; full paper not read.
• Jastreboff AM, et al. Phase 2 retatrutide trial. N Engl J Med. Published June 26, 2023. Journal DOI; reproduced paper read; supplementary appendix read, Table S14.
• Eli Lilly releases: December 11, 2025 (TRIUMPH-4); July 23, 2026 (TRIUMPH-2 and -3); September 29, 2026 (TRIUMPH-2 detailed results).
• Lilly Medical: Dysesthesia in the TRIUMPH trials (displays last reviewed August 18, 2026); retatrutide expanded-access program (last reviewed August 26, 2026).
• FDA: Wegovy prescribing information (revised June 2026), also checked against Novo Nordisk's current prescribing information; concerns with unapproved GLP-1 drugs; MedWatch.
• Eli Lilly. Zepbound prescribing information. Revised August 2026; section 6.1, Dysesthesia.
• Medsafe (New Zealand). GLP-1 receptor agonists and altered skin sensations. March 5, 2026.
• Victorian Department of Health. Toxicity linked to unapproved peptide labelled retatrutide. Alert issued June 19, 2026; still accessible when checked.
• MedlinePlus: Numbness and tingling; FAST: how to spot a stroke; cellulitis.
• CDC. Shingles symptoms and complications.
• NIH Office of Dietary Supplements. Zinc fact sheet.
• International Association for the Study of Pain. Terminology.
• National Capital Poison Center. Get help for a poisoning.